tricyclo<3.3.1.1^3,7>dec-2-yl (S)-<1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-1-<(1-phenylethyl)amino>ethyl>carbamate | 130406-44-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: tricyclo<3.3.1.1^3,7>dec-2-yl (S)-<1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-1-<(1-phenylethyl)amino>ethyl>carbamate
• 英文别名: tricyclo<3.3.1.1^3,7>dec-2-yl(S)-<1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-<(2-phenylethyl)amino>ethyl>carbamate；tricyclo[3.3.1.1^3,7]dec-2-yl (S)-{1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-1-[(1-phenylethyl)amino]ethyl}carbamate；[(S)-2-(1H-Indol-3-yl)-1-methyl-1-phenethylcarbamoyl-ethyl]-carbamic acid adamantan-2-yl ester；2-adamantyl N-[(2S)-3-(1H-indol-3-yl)-2-methyl-1-oxo-1-(2-phenylethylamino)propan-2-yl]carbamate
• CAS: 130406-44-9
• 化学式: C₃₁H₃₇N₃O₃
• 分子量: 499.653
• InChiKey: RGFJPHVCLXSEHE-GYSLRPEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  83.2
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-金刚烷醇 在 吡啶 、 lithium hydroxide 、 五氟苯酚 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 86.25h， 生成 tricyclo<3.3.1.1^3,7>dec-2-yl (S)-<1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-1-<(1-phenylethyl)amino>ethyl>carbamate
  参考文献：
  名称：

  合理设计CCK的“二肽”类似物。α-甲基色氨酸衍生物，具有高度的抗焦虑特性，是具有高选择性和口服活性的胃泌素和CCK-B拮抗剂。

  摘要：

  本文介绍了合成和结构-活性关系（SAR），从而导致了神经肽胆囊收缩素（CCK）的“二肽”类似物的第一个合理设计。化合物[R-（R *，S *）]-4- [2- [3-（1H-吲哚-3-基）-2-甲基-1-氧代-2-[（三环[3.3.1.1（3 ，7）]癸-2-基氧基）羰基]氨基]丙基]氨基] -3-苯基丙基]-氨基] -4-氧代-2-丁烯酸，[R-（R *，R *）]-4- [2- [3-（1H-吲哚-3-基）-2-甲基-1-氧-2-（[三环[3.3.1.1（3,7）]癸-2-氧）羰基]氨基]丙基]氨基] -1-苯乙基]氨基] -4-氧代-2-丁烯酸和[R-（R *，R *）]-4- [2- [3-（1H-吲哚-3-基） -2-甲基-1-氧代-2-[（（三环[3.3.1.1（3,7）]癸-2-基氧基）羰基]氨基]丙基]氨基] -1-苯基乙基]氨基] -4-氧代丁酸（29d）的CCK-B结合亲和力IC50

  DOI：

  10.1021/jm00105a062

文献信息

• Rationally designed "dipeptoid" analogs of CCK. .alpha.-Methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties
  作者：David C. Horwell、John Hughes、John C. Hunter、Martyn C. Pritchard、Reginald S. Richardson、Edward Roberts、Geoffrey N. Woodruff

  DOI：10.1021/jm00105a062

  日期：1991.1

  This paper describes the synthesis and structure-activity relationships (SAR) leading to the first rational design of "dipeptoid" analogues of the neuropeptide cholecystokinin (CCK). Compounds [R-(R*,S*)]-4-[2-[3-(1H-indol-3-yl)-2-methyl-1-oxo-2-[(tricyclo [3.3.1.1(3,7)]dec-2-yloxy)carbonyl]amino]propyl]amino]-3- phenylpropyl]-amino]-4-oxo-2-butenoic acid, [R-(R*,R*)]-4-[2-[3-(1H-indol-3-yl)-2-met

  本文介绍了合成和结构-活性关系（SAR），从而导致了神经肽胆囊收缩素（CCK）的“二肽”类似物的第一个合理设计。化合物[R-（R *，S *）]-4- [2- [3-（1H-吲哚-3-基）-2-甲基-1-氧代-2-[（三环[3.3.1.1（3 ，7）]癸-2-基氧基）羰基]氨基]丙基]氨基] -3-苯基丙基]-氨基] -4-氧代-2-丁烯酸，[R-（R *，R *）]-4- [2- [3-（1H-吲哚-3-基）-2-甲基-1-氧-2-（[三环[3.3.1.1（3,7）]癸-2-氧）羰基]氨基]丙基]氨基] -1-苯乙基]氨基] -4-氧代-2-丁烯酸和[R-（R *，R *）]-4- [2- [3-（1H-吲哚-3-基） -2-甲基-1-氧代-2-[（（三环[3.3.1.1（3,7）]癸-2-基氧基）羰基]氨基]丙基]氨基] -1-苯基乙基]氨基] -4-氧代丁酸（29d）的CCK-B结合亲和力IC50
• HORWELL, DAVID C.;HUGHES, JOHN;HUNTER, JOHN C.;PRITCHARD, MARTYN C.;RICHA+, J. MED. CHEM., 34,(1991) N, C. 404-414
  作者：HORWELL, DAVID C.、HUGHES, JOHN、HUNTER, JOHN C.、PRITCHARD, MARTYN C.、RICHA+

  DOI：——

  日期：——
• Rationally designed ‘dipeptoid’ analogues of cholecystokinin (CCK): N-terminal structure-affinity relationships of α-methyl-tryptophan derivatives
  作者：JM Eden、M Higginbottom、DR Hill、DC Horwell、JC Hunter、K Martin、MC Pritchard、SS Rahman、RS Richardson、E Roberts

  DOI：10.1016/0223-5234(93)90077-r

  日期：1993.1

  The structure-affinity relationships (SAR) between the N-terminii of a series of alpha-methyl-tryptophanylphenethylamide derivatives and the cholecystokinin (CCK) B receptor are discussed. A series of compounds with the general formula R-X-alpha-methyl-tryptophanylphenethylamide was prepared, where R is a cycloalkyl, a bicycloalkyl or a tricycloalkyl group and X is a urethane, thiourethane, amide, urea or a sulphinamide linking group. The CCK-B receptor binding affinities of these are discussed. The SAR form part of a systematic program for the rational design of 'dipeptoid' analogues of the neuropeptide CCK. Beginning with 1,1-dimethylpropyl (+/-)-[1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]ethyl]carbamate (IC50 = 4720 nM on CCK-B binding affinity) the N-terminal moiety was systematically changed for groups of varying size, shape and lipophilicity until the optimal N-terminal group was obtained and the favoured linking group chosen, resulting in the compound tricyclo[3.3.1.1(3,7)]dec-2-yl(R)-[(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[(2-phenylethyl)amino]ethyl]carbamate with an IC50 = 32 nM on CCK-B receptor binding affinity.